IVVD · Invivyd, Inc.
$0.83
-0.01 (-1.08%)
At close · Sep 4
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on current operating plans and excluding future external financing, the Company will not have sufficient cash and cash equivalents to fund its operating expenses and capital requirements beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$243.47M
Shares
294.76M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.83
Open$0.82
Day$0.79–0.83
52W close$0.54–2.88
Avg vol 30d3.9M
Short int30.9M · 10.5% float · 11.2d
Short vol71%
Last earningsAug 13, 2026
DataAug 2021–Sep 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 26, 2026
Est · unconfirmed
· in 11 wks
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$58.37M
Trailing 12 months
Net income (TTM)
−$107.33M
Trailing 12 months
Revenue growth YoY
+21.2%
Year over year
Operating margin
-192.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-45.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$160.08M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+167.0%
Year over year · more shares
Price change (1Y)
-17.2%
Trailing year
Short interest
10.5%
Latest settlement · 11.2 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−45%
below
Price vs 50-day avg
+7%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
12%
near low
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+12%
trailing
6-month return
−51%
trailing
YTD return
−67%
this year
Relative strength
−66%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.49% of float · ▲ +11.2% MoM · 11.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
126 holders — mid 3-yr range
Squeeze score
82
high risk · 0–100
Fundamentals
Revenue growth
+110%
Y/Y
EPS growth
+79%
Y/Y
Free cash flow
$-58.3M
Quant / Vol
risk profile
Volatility
112%
annualized · 1-yr
Max drawdown
−81%
past year
ATR
10.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Prior guidance
period ended
· from the 8-K filed Aug 14, 2024
2024 net product revenue
· 2024
$150M – $200M
Cash and cash equivalents (year-end)
· 2024
at least $75M
Year-end cash position
· 2024 year-end
$75M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−45%
Bearish
Price vs 50-day avg
+7%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
12%
Bearish
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +34 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
10.49% of float · ▲ +11.2% MoM · 11.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
126 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 12%
Range high $3
vs 200-day avg -45%
vs 50-day avg +7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IVVD
this stock
Invivyd, Inc.
|
$243.47M | -66.6% | +110.5% | — | 10.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.42B | +20.5% | +46.2% | 31.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.22B | +7.2% | +20.8% | 20.5 | 2.3% |
|
ARGX
Argenx SE
|
$64.25B | +22.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$60.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IVVD | -14.4% | +11.6% | -50.5% | -13.5% | -66.6% |
| SPY | +0.1% | -0.4% | +15.1% | +0.4% | +12.9% |
| vs SPY | -14.5% | +12.0% | -65.7% | -13.9% | -79.5% |
Key facts
CIK
1832038
CUSIP
00534A102
13F (30d)
94 filings
94 filers
Visit website
Investor relations